In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

Francis P. Worden, MD, discusses his key takeaways for other oncologists treating patients with radioidine-refractory differentiated thyroid cancer.

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line treatment in HER2-positive breast cancer after recording “highly ...

Patients treated with trastuzumab deruxtecan + pertuzumab had a statistically significant and clinically meaningful improvement in PFS compared with standard of care. Topline results were ...

The improvement in progression-free survival (PFS) was seen across a broad spectrum of patients in the study and marks the first time ... as a second-line or later therapy for HER2-positive ...

The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus ...

In nonsquamous NSCLC, novel agents, such as pemetrexed and bevacizumab, have improved survival in the first-line setting. Maintenance therapy with pemetrexed and erlotinib resulted in improved ...

Health care professionals should assess baseline bone mineral density in patients with osteoporosis before determining ...

A new study published in the journal of BMC Gastroenterology showed that insulin resistance was quite common in non-diabetic ...

“This is a significant milestone for patients and sets the foundation for ENHERTU in combination with pertuzumab as an important treatment option in the first-line HER2 positive setting.

It is estimated that acute GvHD occurs in approximately half of HSCT patients, and half of those cases do not respond to treatment with steroids, the standard first-line treatment. In patients who ...

This is a significant milestone for patients and sets the foundation for ENHERTU in combination with pertuzumab as an important treatment option in the first-line HER2-positive setting.” ...